Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories (RTSL) Cost of Revenue (2020 - 2021)

Rapid Therapeutic Science Laboratories' Cost of Revenue history spans 2 years, with the latest figure at $200.0 for Q2 2021.

  • For Q2 2021, Cost of Revenue fell 98.92% year-over-year to $200.0; the TTM value through Mar 2022 reached $200.0, down 99.14%, while the annual FY2021 figure was $200.0, 98.97% down from the prior year.
  • Cost of Revenue for Q2 2021 was $200.0 at Rapid Therapeutic Science Laboratories, down from $4791.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $18556.0 in Q2 2020 and bottomed at $200.0 in Q2 2021.